patients at high risk for cardiovascular events - angiotensin-receptor blockers - all type of patients clinical trials results meta-analysis

<h1> <a href="TM36-4-angiotensin-receptor blockers-patients at high risk for cardiovascular events" > <strong>patients at high risk for cardiovascular events</strong> - angiotensin-receptor blockers </a> - all type of patients trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="../TRC_t6741.htm"> ONTARGET (telmisartan alone), 2008 </a> <br> NCT00153101 </td> <td> telmisartan 80mg daily<br>  <i>versus</i> <br> ramipril 10 mg daily </td> <td> patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage </td> <td> follow-up 4.7y<br> n=8542/8576<br> Parallel groups<br> double blind <br> 40 countries </td> </tr> <tr> <td> <a href="../TRC_t6743.htm"> ONTARGET (association vs ramipril), 2008 </a> <br> NCT00153101 </td> <td> telmisartan 80mg + ramipril 10mg daily<br>  <i>versus</i> <br> ramipril 10 mg daily </td> <td> patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage </td> <td> follow-up 4.7y<br> n=8502/8576<br> Parallel groups<br> double blind <br> 40 countries </td> </tr> <tr> <td> <a href="../TRC_t7111.htm"> VALUE, 2004 </a> <br> NCT00129233 </td> <td> valsartan based regimen<br>  <i>versus</i> <br> amlodipine based regimen </td> <td> patients, aged 50 years or older with treated or untreated hypertension and high risk of cardiac events </td> <td> follow-up 4.2 y (mean)<br> n=7649/7596<br> Parallel groups<br> Double blind <br> 31 countries </td> </tr> <tr> <td> <a href="../TRC_t7112.htm"> SCOPE, 2003 </a> <br> </td> <td> candesartan<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up 3.7y (mean)<br> n=2477/2460<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t7113.htm"> LIFE, 2002 </a> <br> </td> <td> losartan<br>  <i>versus</i> <br> atenolol </td> <td> patients aged 55–80 years, with previously treated or untreated hypertension (sitting blood pressure 160–200/ 95–115 mm Hg) and ECG signs of LVH. </td> <td> follow-up 4.8 y (mean)<br> n=4605/4588<br> Parallel groups<br> Double blind <br> USA, Europe </td> </tr> <tr> <td> <a href="../TRC_t8402.htm"> ONTARGET (association vs telmisartan), 2008 </a> <br> NCT00153101 </td> <td> telmisartan 80mg + ramipril 10mg daily <br>  <i>versus</i> <br> telmisartan 80 mg daily </td> <td> patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage </td> <td> follow-up 4.7y<br> n=8502/8542<br> Parallel groups<br> double blind <br> 40 countries </td> </tr> <tr> <td> <a href="../TRC_t8595.htm"> TRANSCEND, 2008 </a> <br> NCT00153101 </td> <td> telmisartan 80 mg/day<br>  <i>versus</i> <br> placebo </td> <td> high-risk patients intolerant to angiotensin-converting enzyme inhibitors </td> <td> follow-up median 56 months (IQR 51-64)<br> n=2954/2972<br> Parallel groups<br> double blind <br> 40 countries </td> </tr> <tr> <td> <a href="../TRC_t9135.htm"> PROPHESS, 2008 </a> <br> NCT00153062 </td> <td> telmisartan 80 mg daily<br>  <i>versus</i> <br> placebo </td> <td> patients who recently had an ischemic stroke </td> <td> follow-up 2.5 y<br> n=10146/10186<br> Factorial plan<br> double blind <br> 35 countries </td> </tr> <tr> <td> <a href="../TRC_t9886.htm"> KYOTO HEART Study, 2009 </a> <br> NCT00149227 </td> <td> valsartan (titrated up to 160mg daily)<br>  <i>versus</i> <br> non ARB treatment </td> <td> Uncontrolled hypertensive patients with high risk of cardiovascular events </td> <td> follow-up 3.27 y<br> n=1517/1514<br> Parallel groups<br> open <br> Japan </td> </tr> <tr> <td> <a href="../TRC_t10422.htm"> Ruilope, 2010 </a> <br> </td> <td> LCZ696 for 8 weeks<br>  <i>versus</i> <br> placebo </td> <td> patients with mild to moderate hypertension </td> <td> follow-up 8 weeks<br> n=-9/-9<br> Parallel groups<br> double blind <br> 18 countries </td> </tr> </table> <h2>References</h2> <p> <b>ONTARGET (telmisartan alone), 2008 : </b> Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson CTelmisartan, ramipril, or both in patients at high risk for vascular events. <i>N Engl J Med 2008 Apr 10;358:1547-59</i> [PMID 18378520] 10.1056/NEJMoa0801317 </p> <p> <b>ONTARGET (telmisartan alone), 2008 : </b> Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf SEffects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. <i>Circulation 2009;120:1380-9</i> [PMID 19770395] </p> <p> <b>ONTARGET (association vs ramipril), 2008 : </b> Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson CTelmisartan, ramipril, or both in patients at high risk for vascular events. <i>N Engl J Med 2008 Apr 10;358:1547-59</i> [PMID 18378520] </p> <p> <b>RENAAL, 2001 : </b> Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar SEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. <i>N Engl J Med 2001;345:861-9</i> [PMID 11565518] </p> <p> <b>VALUE, 2004 : </b> Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti AOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. <i>Lancet 2004 Jun 19;363:2022-31</i> [PMID 15207952] </p> <p> <b>SCOPE, 2003 : </b> Zhu H, Sagnella GA, Dong Y, Miller MA, Onipinla A, Markandu ND, MacGregor GAContrasting associations between aldosterone synthase gene polymorphisms and essential hypertension in blacks and in whites. <i>J Hypertens 2003 Jan;21:87-95</i> [PMID 12544440] </p> <p> <b>LIFE, 2002 : </b> Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel HCardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. <i>Lancet 2002 Mar 23;359:995-1003</i> [PMID 11937178] </p> <p> <b>ONTARGET (association vs telmisartan), 2008 : </b> Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson CTelmisartan, ramipril, or both in patients at high risk for vascular events. <i>N Engl J Med 2008 Apr 10;358:1547-59</i> [PMID 18378520] </p> <p> <b>PROPHESS, 2008 : </b> Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, | <i>N Engl J Med 2008;359:1225-37</i> [PMID 18753639] 10.1056/NEJMoa0804593 </p> <p> <b>KYOTO HEART Study, 2009 : </b> Sawada T, Yamada H, Dahlöf B, Matsubara HEffects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. <i>Eur Heart J 2009 Aug 31;:</i> [PMID 19723695] </p> <p> <b>Ruilope, 2010 : </b> Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MPBlood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. <i>Lancet 2010 Mar 15;:</i> [PMID 20236700] 10.1016/S0140-6736(09)61966-8 </p>